Trial Profile
A Randomised, Double-blind, Placebo Controlled Study to Determine the Safety, Pharmacokinetics and Efficacy of Topical ZPL-5212372 Ointment Administered BID for up to 2 Weeks in Healthy Subjects and Subjects With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2019
Price :
$35
*
At a glance
- Drugs ZPL 5212372 (Primary) ; Sarilumab
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept
- Sponsors Ziarco
- 20 Mar 2017 Status changed from recruiting to completed.
- 09 Jun 2016 Status changed from planning to recruiting.
- 03 Feb 2016 New trial record